Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Abstract

With the emergence of high-throughput discovery platforms, robust preclinical small-animal models, and efficient clinical trial pipelines, it is becoming possible to envision a time when the treatment of human neurologic diseases will become personalized. The emergence of precision medicine will require the identification of subgroups of patients most… (More)
DOI: 10.1212/WNL.0000000000000652

Topics

Cite this paper

@article{Gutmann2014EliminatingBT, title={Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.}, author={David H. Gutmann}, journal={Neurology}, year={2014}, volume={83 5}, pages={463-71} }